Global Vasculitis Pipeline Insights | Clinical Trials Evaluation Research Report 2022 by DelveInsight

Vasculitis Pipeline constitutes 30+ key companies continuously working towards developing 30+ Vasculitis treatment therapies, analyzes DelveInsight

DelveInsight's 'Vasculitis Pipeline Insight 2022' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Vasculitis pipeline domain.

Find a sample copy of the Vasculitis Pipeline report - https://www.delveinsight.com/sample-request/vasculitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kupr

Some of the essential takeaways from the Vasculitis Pipeline report:

1. DelveInsight's Vasculitis Pipeline analysis depicts 30+ active players proactively working to develop 30+ pipeline treatment therapies.
2. Some of the key Dengue companies working to develop potential drug candidates to improve the Vasculitis treatment scenario include CytoDyn, ChemoCentryx, Hoffman-la-Roche, GlaxoSmithKline, Vifor Pharma, R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, Beijing Defengrei Biotechnology, InflaRx, Janssen Biotech, Novartis, AbbVie, Oxitope Pharma, InflaRx, Eli Lilly and company, Toleranzia, Travere Therapeutics, Caladrius Biosciences, Caladrius Biosciences, Yake Biotechnology, and many others.
3. Essential Vasculitis pipeline therapies such as AMB 301, Research, program: kidney disorder therapeutics, BDB 1, Vilobelimab, Guselkumab, Secukinumab, Upadacitinib, CCX-168, Belimumab, and others are under development in different phases of clinical studies.
4. In October 2021, Novartis Pharmaceuticals initiated a randomized, parallel-group, double-blind, placebo-controlled multicenter Phase III trial to investigate the efficacy and safety of Secukinumab 300 mg administered subcutaneously versus placebo, in combination with glucocorticoid taper regimen, in patients With Giant Cell Arteritis (GCA).
5. Chemocentryx has launched TAVNEOS in the fourth quarter of 2021 following FDA approval on October 8, 2021, as an adjunctive treatment in adult patients with severe active ANCA-associated vasculitis, specifically granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis, in combination with standard therapy including glucocorticoids.
6. ChemoCentryx received approval from European Union (EU) for its drug, Tavneos (avacopan), to treat adult patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis) in January 2022.
7. In November 2021, InflaRx reported positive data from the European Phase II IXCHANGE study of vilobelimab, a first-in-class anti-C5a antibody, in patients with ANCA-associated vasculitis (AAV). The study achieved its principal objective, demonstrating comparable clinical response of vilobelimab to the standard of care, while significantly reducing the need for glucocorticoid (GC) treatment.
8. In November 2021, U.S. FDA's Office For Orphan Products Development (OOPD) granted the orphan drug status for Ambulero's gene therapy candidate, AMB-301, to treat Buerger's Disease (BD), also known as Thromboangiitis Obliterans (TAO).
Upadacitinib (ABT-494) is a JAK1 selective inhibitor being investigated in Phase III clinical trial to treat Giant Cell Arteritis.
9. Sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), is a novel investigational product candidate in the Phase II stage of development.

Request a sample and discover more about the scope of the report offerings @ https://www.delveinsight.com/sample-request/vasculitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kupr

The Vasculitis pipeline report lays down detailed profiles of the pipeline assets, comparative analysis of clinical and non-clinical stage Vasculitis products, inactive and dormant assets, comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the Vasculitis pipeline landscape.

For further information on the Vasculitis current pipeline therapeutics, reach out @ https://www.delveinsight.com/report-store/vasculitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kupr

Vasculitis Overview

Vasculitis involves inflammation of the blood vessels. The inflammation can cause the walls of the blood vessels to thicken, which reduces the width of the passageway through the vessel. If blood flow is restricted, it can result in organ and tissue damage. Vasculitis can affect people at any age. Some forms affect blood vessels that go to or supply specific organs like your skin, eyes, or brain. Vasculitis symptoms are very commonly observed symptoms such as fever, loss of appetite, weight loss, and fatigue.
The most common forms of Vasculitis are Giant cell arteritis, Polymyalgia rheumatica, Polyarteritis nodosa, and Granulomatosis with polyangiitis. Whereas, different types of Vasculitis are Large Vessel Vasculitis, Medium Vessel Vasculitis, and Small Vessel Vasculitis.

Vasculitis treatment depends on what's causing your Vasculitis and which organs are affected. Corticosteroid medications, also known as steroids, are generally preferred to fight inflammation.

Find out more about the disease and recently developing strategies @ https://www.delveinsight.com/report-store/vasculitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kupr

Vasculitis Therapeutics Assessment

The Vasculitis Pipeline report proffers an integral view of the Vasculitis emerging novel therapies segmented by Stage, Product Type, Mechanism of Action, Route of Administration, and Molecule Type.

Scope of the Vasculitis Pipeline Report

Coverage: Global

Therapeutic Assessment By Vasculitis Product Type: Mono, Combination, Mono/Combination

Therapeutic Assessment By Vasculitis Clinical Trial Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Pre-registration, Inactive candidates
Therapeutics Assessment By Vasculitis

Therapeutics Route of Administration: Oral, Intravenous, Inhalation, Subcutaneous

Therapeutics Assessment By Vasculitis Therapies Molecule Type: Gene therapy, Stem cell therapy, Small molecules

Therapeutics Assessment By Vasculitis Therapies Mechanism of Action: Interleukin-23 subunit p19 inhibitors, Janus kinase 1 inhibitor, IL17A protein inhibitors, Complement C5a inhibitors, E-selectin stimulants, E-selectin stimulants, Gene transference, Immunomodulators, TYK2 kinase inhibitors, Antibody-dependent cell cytotoxicity, Apoptosis stimulants

Key Vasculitis Companies: CytoDyn, ChemoCentryx, Hoffman-la-Roche, GlaxoSmithKline, Vifor Pharma, R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, Beijing Defengrei Biotechnology, InflaRx, Janssen Biotech, Novartis, AbbVie, Oxitope Pharma, InflaRx, Eli Lilly and company, Toleranzia, Travere Therapeutics, Caladrius Biosciences, Caladrius Biosciences, Yake Biotechnology, and others.

Key Vasculitis Pipeline Therapies: AMB 301, Research program: kidney disorder therapeutics, BDB 1, Vilobelimab, Guselkumab, Secukinumab, Upadacitinib, CCX-168, Belimumab, and others

Dive deep into rich insights for emerging drugs and pipeline assessment, visit @ https://www.delveinsight.com/report-store/vasculitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kupr

Table of Contents
1. Introduction
2. Executive Summary
3. Vasculitis: Overview
4. Pipeline Therapeutics
5. Late Stage Products (Phase III)
5.1. Secukinumab: Novartis
6. Early Stage Products (Phase I/II)
6.1. BDB 1: Beijing Defengrei Biotechnology
7. Preclinical Stage Products
7.1. AMB 301: Ambulero
8. Discovery Stage Products
9. Therapeutic Assessment
10. Inactive Products
11. Collaborations Licensing / Partnering / Funding
12. Vasculitis - Unmet Needs
13. Vasculitis - Market Drivers and Barriers
14. Appendix
15. About DelveInsight

Get the TOC of the Vasculitis Pipeline report here, https://www.delveinsight.com/report-store/vasculitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kupr

Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.

This release was published on openPR.